InveniAI, a global leader in the application of artificial intelligence (“AI”) and machine learning (“ML”) tools to revolutionize drug discovery and development, has closed on its recent debt financing. According to the announcement, the financing was for an estimated $3.1 million. InveniAI is focused on transforming the discovery and development of life-changing therapies and products with AI-powered technology; the company’s objective is to improve human health and the quality of life. InveniAI has been working for more than a decade to solve real-world problems for the pharmaceutical industry. The company’s efforts led to the creation of an industry-leading technology platform: AlphaMeld(R), which has been crucial in delivering significant clinical, transactional and strategic impact for more than 150 biopharma industry collaborations. ThinkEquity served as an advisor to the InveniAI on the debt financing transaction.
About InveniAI LLC
InveniAI LLC stands as a global frontrunner in the application of artificial intelligence (“AI”) and machine-learning (“ML”) tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, InveniAI utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company’s pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. For additional information about the company, please visit www.InveniAI.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
